Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.
On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.5 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.21 per share a year ago.
Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street ​estimates, citing resilient demand for routine diagnostic testing.
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted dilute
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES
DGX heads into Q1 earnings with steady growth expectations, but estimate cuts and a negative ESP could temper the outlook.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capital Management Associates Inc acquired a new stake in shares of Quest Diagnostics Incorporated (NYSE: DGX) in the undefined quarter, according to the company in its most recent disclosure with the
Foster and Motley Inc. lowered its position in Quest Diagnostics Incorporated (NYSE: DGX) by 20.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Delta Capital Management LLC reduced its stake in Quest Diagnostics Incorporated (NYSE: DGX) by 12.8% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 17,710
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE